Robert Blum
With over 20 years of leadership and successes like MyoKardia, CEO Blum seeks to elevate Cytokinetics to the stature of Gilead or Genentech.
Although no drug has launched in two decades, Blum’s enthusiasm and fundraising skills have sustained Cytokinetics, leading to favorable Phase 3 afikomten data.
Blum’s leadership and financial expertise receive praise from former peers, who also highlight his habit of setting high targets and micromanaging.
By submitting this form, you are agreeing to ManagementTrack’s Privacy Policy. You can choose to opt out of marketing or advertising emails using the ‘unsubscibe’ link included in our emails.
The best
The best
The best
Our investigative journalists interview the top former colleagues of the CEOs you care about.
Our former buysider analysts summarize the key strengths & weaknesses, past successes & failures, and ability to drive value going forward.
You get access to the actual anonymized transcripts and insights.